IN the past many chemicals have been recommended for intravenous injection or for introduction into the body in other ways with the object of directly killing infecting bacteria. With the exception of the salvarsan group they have been found wanting, although sometimes one and sometimes another has had, for a time, a certain vogue.
Let us see what happens when the antibacterial action of these chemicals is tested in human blood; and we may take as an example quinine, which has been recommended as an intravenous injection for the treatment of puerperal septicoemia due to Streptococcus pyogenes. If human defibrinated blood infected with a suitable dose of Streptococcus pyogenes is mixed with serial dilutions of quinine and incubated in slide cells the resulting growth is as illustrated in fig. 1 .
In the blood without quinine there is no growth as the phagocytes of the blood can deal with all of the infecting bacteria. In the weakest concentrations of quinine there is the same result, but as the concentration of quinine increases so haemolytic colonies of streptococci appear until when there is a concentration of 1: 4,000 in the blood all the streptococci implanted in the blood grow out. This is due to the fact that chemicals like quinine have a more poisonous action on leucocytes than they have on streptococci. Had it been possible to administer quinine in a dose sufficient to produce in the blood a concentration of 1: 4,000 the result would have been serious as the blood would have lost all its anti-streptococcal power and have become a first-class culture medium for the streptococcus. The dose recommended was, however, 2 gr., which if introduced into the blood-stream could not give a concentration of more than 1: 40,000. It will be seen by referring to fig. 1 that this concentration is well off the scale, and would have no effect on the bacteria or on the leucocytes.
When sulphanilamide was introduced I wInterested to see whether it had any such antileucocytic action. The test was made in exactly the same way except that the indicator organism was a haemolytic enterococcus a microbe which is quite insensitive to sulphanilamide. The result obtained is shown in fig. 2 .
This shows that there is no antileucocytic effect until a concentration of sulphanilamide of 1: 400 is reached a concentration far greater than can be attained in the blood therapeutically. More recently similar experiments were made with M & B 693 and it was likewise found that this drug had no antileucocytic effect in any significant concentration.
A very different picture is obtained when the antibacterial power of sulphanilamide or M & B 693 is tested on a sensitive microbe such as the Streptococcus pyogenes. If such a test is made in exactly the same way as is illustrated in fig. 1 The light patches represent areas of haemolysis causedlby growvth of the streptococci.
M & B 693 appears to be ten times stronger than sulphanilamide on a typical Group A haemolytic streptococcus. Here it can be seen that in human blood some antibacterial action is manifest in concentrations of the drugs far x , eaker than can be obtained by their oral administration. It can also be seen that on Streptococcus pyogenes M & B 693 is something like ten times as potent as sulphanilamide. (Complete inhibition of growth with 1: 1,000,000 of M & B 693 and 1: 109,000 of sulphanilamide.)
Leaving aside the question of toxicity of such drugs a simple test of this nature gives very valuable information; a result such as is shown in fig. 3 gives a very strong indication that therapeutic success would follow the administration of these drugs.
A criticism might be offered that it is easy to say this now that sulphanilamide and 693 have proved themselves therapeutically successful, but I first published this method of testing antibacterial chemicals in 1924 and it has appeared since in various publications including the Proceedings of this Society.
The exact mode of action of drugs like sulphanilamide or M & B 693 is still unsettled, but it is generally accepted that the action is on the infecting bacteria and not on the host ; and that it is bacteriostatic rather than bactericidal. The chief result of the drug on the bacteria is some interference with their growth, and this is well brought out in tw-o experiments which I have already published (1938) .
Demonstration of the Bacteriostatic Action of _M & B 693 on Pneuniococci
Human blood was deprived of its leucocytes by passing it through a tight cottonwool filter. Such deleucocyted blood has no antibacterial action on pneumococci. This blood was infected with a suitable dilution of a pneumocoecus culture and was mixed in equal volumes with serial dilutions of M & B 693 in normal saline. The mixtures were incubate(d in slide cells for twenty-four hours, wN-hen the resultant growAth wNas noted. The results obtained are shown in Table 1 . This shows that the druig in a concentration of 1: 8,000, which is about the maximum which can be obtained in the body therapeutically, has no bactericidal action on pneumococci, but there is a marked inhibition of growth as shown by the very small size of the colonies in all concentrations greater than 1: 250,000.
With a more sensitive microbe such as the Streptococcus pyogenes inhibition of growth may be complete, and even after prolonged incubation no colonies appear but the cocei may still survive as is shown in the next experiment.
Serum from a patient who was taking M & B 693 in large doses was infected Mwith a sensitive Streptococcus pyogenes so that 25 c.mm. of the serum contained 115 cocci. This infected serum was incubated in 25 c.mm. volumes in capillary tubes, and at intervals the whole of the contents of one tube were planted into glucose broth to ascertain whether the streptococci had been killed. The result obtained was as follows 18 hours Planted in glucose broth after 24 hoursgrowth 48 hours It was estimated chemically that this sample of serum contained M & B 693 in a concentration of 1: 10,000, but it is clear that 25 c.mm. could not kill 115 streptococci in two days.
As these drugs do not actually kill the infecting bacteria something else must do it to account for the striking success which has followed their use in experimental infection of animals and in medical practice. That something is the natural defensive mechanism of the body which, while it might be powerless against a rapidly growing streptococcal or pneumococcal infection, can cope with the infection when the growth of the bacteria is interfered with by the drug.
Even with the most sensitive organisms these drugs do not effect a cure in every case, and I am bringing forward evidence to show that the results obtained by increasing the power of the defensive mechanism, in other words, by increasing the immunity, are, in combination with these drugs, far superior to immunotherapy or chemotherapy alone. The immunity can be increased specifically by vaccine and serums and non-specificially by a great variety of measures.
Passive Imm?inity in Association with Chemotherapy
Several workers have shown that specific antiseruiiis enhance the apparent effect of sulphanilamide treatment.
De and Basu (1938), working with staphylococcus, use(d a combination of an antitoxic and an antibacterial serum, and showed that mice infected with staphylococci could be saved by the administration of these serums combine(d with sulphanilamide treatment although neither the serum nor the sulphanilamide treatment saved the animals. Adapted from De and Basii. Fig. 4 , which is adapted from the figures given by De and Basu, shows graphically the results which they obtained. All the controls died, all the animals having the combined treatment lived, and only a few survived that had serum or chemotherapy alone.
Of greater interest possibly are the results published by Loewenthal (1939) on the synergic action of antistreptococcal serum and sulphanilamide in experimental streptococcal infections in mice.
Loewenthal chose a dose of serum which he knew would not protect the mice against his experimental infection, and likewise a dose of sulphanilamide too small 914 Section of Obstetrics acnd Gynwecology 915 to be completely effective. In one series of experiments he gave the serum eighteen hours before the animals were infected and then imme(liately after infection the mice received orally a single dose of suilphanilamide. I bave set forth graphically in fig the results which he obtained, which show clearly that even with a very smnall dose of sulphanilamide a greater nutmber of the serum-treated animals survived; and wN-ith a dose of 25 mgIn. all the mice recovered although in the control series only one out of four survived.
In a second series the mice were infected with streptococci and nothing wAas done for eighteen hours, by which time the mice w-ere very ill.
Then the mice were divided into four batches, which were treated as followrs
(1) 0.5 c.c. of normal rabbit serum.
(2) 0.5 c.c. of antistreptococcal serum (rabbit). It is icea r fi-om thils thlat tlc heombiniiation of' m nonell( serrun11 and Al & 1B 693 xx as thle uni1v one, effective in preventiwtiti te toxthof pneieltm)(o(occ in human blood, and thiere is, little d(oubt that the 50a1n' combinatiotn \\-Ill be most effe(ctive in the ti-entinient of p'ic'lnoll 111 Huma. You Wvill see, hoxwevetr, that wh-len the leuc(oevtes ar-e removed f'rom the 1)100( tlue combination ot' Al & 13 693 and imiminiite serum11 is w ithout effect. 1 (icc/l( Thi/py 1lit A4s8,,oritihon wii'th C(hi/oth( i'atpy WNe hanve seen that p)assive imnmnnity hy means of' serumii hais ac striking effec-t x hieni indIu'edl in association withi tr-eatmienit 1)v sulphlanil-amidle or Al & B 693. In p)assive immnunity r-eady tor'med antibodfies are Introdulcedl iitlt( the inifectedi atninmal, hoit thiere is o reason wxhy the anlincal slhonl(l niot make its,.xxown antibodies in response, to a vaccine, andl it is pr'obabOle thiat, if thiere is tlime, the (conc'entration of, anitibodies inl the 1)100 (1 f' the linfecte(l anlillal Imnmnunizedl wxithi a vaccine( WOU011( be munchl gyreater thian it wou011( bec if a therapeutic (lose of' serumii wxas a(lminlistere(l. forw this (lose is of' neces,sity-of' small 1)111k compare(d wxitlh the alm)rnt of' b-loodintebdadxxol thieref.Ore hec greatly dlilutedl. Maclean, Rog-ers atiit imyself', thetrefore, madle exl)en'inienits to ascertain wxhether byv mieans of' a sin-le (lose of' vaccinec sufhicient imnimuiiility could1( be deve'loped1 in. an canlimal to maizke anYu difference to thec results obtainie(l wxhen thie animaiils wxerc inifectedI and then tr-eate(l wxithl \l & B1 698. (Adapted from Maclean, Rogers, and Fleming.) when 1,000 minimum lethal doses of pneumococci were given five out of six mice recovered. From this experiment there is no question as to the synergic action of vaccine therapy and M & B 693 treatment. To confirm this a second experiment was done in the same way except that the dose of vaccine was 100 million instead of 25 million. The results obtained are shown in fig. 8 , and it will be seen that they are essentially the same as in the last experiment.
Further confirmatory tests were done in rabbits, and here the infection of pneumococcus was made intradermally instead of intraperitoneally, as in the case of the mice. The rabbits received a single dose of vaccine six days before they were infected. The control rabbit and the one which received the vaccine, but no M & B 693, died with a pneumococcal septicaemia. The unvaccinated rabbit treated with M & B 693 recovered, but had a very serious illness for four days, during which time pneumococci could be recovered from the blood. The vaccinated rabbit treated with M & B 693 also recovered, but had only a trifling illness, and blood cultures taken at intervals over four days remained sterile. The temperature charts of these last two rabbits are shown in fig. 9 , and these charts illustrate very well the difference which a single dose of vaccine made in the severity of the illness in animals infected with the same number of the same microbes and both treated in exactly the same manner with M & B 693. There is a certain amount of clinical confirmation of these results which we have obtained in animals. Cokkinnis and McElligott (1938) , in a large series of observations BLOOD CULTURE. 'Maclean, Rogers, and Fleming.) on patients suffering from gonococcal infections, have found that better results were obtained when sulphanilamide treatment was withheld for eight to ten days after the onset of the infection. By doing this they obtained a more rapid ;' cure " and a freedom from relapses. Their explanation of this is " that it takes that much time for the body to acquire enough immunity to dispose of the organisms arrested by sulphanilamide ". They give an interesting table which I have condensed, showing the results obtained in patients treated during the first week of the disease. These patients consisted of over 100 who had never had the disease before, and about half that number who had suffered previously, and in most of whom the complementfixation test was positive, indicating some degree of increased immunity to the gonococcus. You will see from Table III that much better results were obtained in the second group. Lyons and Mangiaracine (1938) have put forward evidence that the state of immunity of the patient plays a large part in the success or failure of sulphanilamide treatment. They divide acute haemolytic streptococcal infections into three classes:-
(1) The patients have antibacterial antibody to their organisms at the time treatment is started.
(2) No antibacterial antibody is present and there is a negative blood culture with beginning localization of their infection by the process of inflammatory fixation.
(3) There is a bacteriaemia with no antibacterial antibody. In this last class they state that sulphanilamide therapy has failed to sterilize the blood-stream.
More recently Ordman (1939) clear that the duration of pyrexia in the patients who had been prophylactically inoculated with pneumococcal vaccine was, in combination with 693 treatment, much less than in the group which had not been so inoculated.
This clinical evidence is not, of course, conclusive, but it is very significant when taken in conjunction with the experimental evidence which I have given above.
I will conclude by summing up the new chemotherapy by sulphanilamide and M & B 693. These drugs act on certain sensitive bacteria in some way so that their reproduction is retarded or abolished. When this has happened the natural defensive mechanism of the body completes the task by destroying the bacteria. The result, therefore, which will be obtained in any particular case will depend on two things: firstly the sensitiveness of the infecting organism to the drug, and secondly the state of immunity of the patient. I have attempted in Table V to set forth shortly the expectation of a good result in various conditions of immunity and sensitivity of the organism. The ordinary individual may, as regards the common pyogenic organisms, be regarded as having a medium degree of immunity which can be increased actively or passively.
In an acute case one cannot tell whether the infecting organism is one which is very sensitive to these drugs so that, if the patient is to have the best chance, every endeavour should be made at the same time that the drug is administered to increase the immunity by vaccines or serums or by non-specific measures.
Serums are only obtainable for certain infections, but vaccines can be obtained, or can readily be prepared, for practically every acute bacterial infection.
